Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed

Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.

The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance